BHCM
CGEM icon

Brevan Howard Capital Management’s Cullinan Oncology CGEM Stock Holding History

Brevan Howard Capital Management’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-24,078
Closed -$342K – 2136
2026
Q1 		$342K Buy
24,078
+13,108
+119% +$168K ﹤0.01% 1540
2025
Q4 		$114K Sell
10,970
-34,966
-76% -$315K ﹤0.01% 1668
2025
Q3 		$272K Buy
45,936
+26,709
+139% +$196K ﹤0.01% 1614
2025
Q2 		$145K Sell
19,227
-21,372
-53% -$172K ﹤0.01% 1760
2025
Q1 		$307K Buy
40,599
+25,864
+176% +$248K ﹤0.01% 857
2024
Q4 		$179K Buy
+14,735
New +$212K ﹤0.01% 926

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Brevan Howard Capital Management's CGEM Position: Q2 2026 in Review

Brevan Howard Capital Management sold out of Cullinan Oncology (CGEM) in Q2 2026, closing a stake of 24,078 shares — an estimated $342K sold.

Brevan Howard Capital Management first reported a position in CGEM in Q4 2024 and held it in 6 quarters. The position peaked at $342K in Q1 2026. 184 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • Brevan Howard Capital Management reported no remaining Cullinan Oncology position as of Q2 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 24,078 Cullinan Oncology shares in Q2 2026, an estimated $342K.
  • Brevan Howard Capital Management first reported a position in Cullinan Oncology in Q4 2024 and held it in 6 quarters.
  • Brevan Howard Capital Management's Cullinan Oncology position peaked at $342K in Q1 2026.
  • 184 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.